Fuji Pharma: Announcements of individual stocks regarding the determination of matters related to stock acquisition in the stock compensation system.
Fuji Pharma: Succession of manufacturing and sales approval for 3 products from Mitsubishi Tanabe Pharma to Fuji Pharmaceutical
Fuji Pharma: Notice of FSN-013 manufacturing and sales approval application in Japan
Fuji Pharma: Notice of obtaining approval for manufacture and sale of biosuccessors (biosimilars) of ustekinumab (genetically modified) preparations
Fuji Pharma: Notice of an exclusive negotiation rights agreement regarding development and commercialization within Japan for “PH80,” which is currently being developed in the field of women's health
Fuji Pharma: Notice of acquisition of manufacturing and marketing approval for drugs jointly developed with Lotus
Fuji Pharma: Succession of manufacturing and sales approval for the sustainable male hormone preparation “Testinone Depot for Muscle Injection”
Fuji Pharma: Announcement of the launch of our first new supplement brand “LAFILL” for physicians and the launch of the nutritional supplement “Folic Acid+Kestos”
Fuji Pharma: Announcement of the sale of “Nextstellis” in Thailand and the holding of a commemorative lecture
Fuji Pharma: Independent Officer Notification Form
Fuji Pharma: Notice regarding the resignation of an outside director
Fuji Pharma: Articles of association 2022-12-21
Fuji Pharma: Notice of independent director
Fuji Pharma Co Ltd: Inheritance of manufacturing and sales approval for four products from Japanese Pharmaceutical to Fuji Pharmaceutical Industry
Fuji Pharma Co Ltd: Notice of the new listing of the natural progesterone preparation "Avminol"
Fuji Pharma Co Ltd: On the reduction of the amount of Capital Reserve
Fuji Pharma Co Ltd: Notice on domestic Business Cooperation of Cervical Canal curing Agent "10 mg for Plopez vagina"
Fuji Pharma Co Ltd: Notice of Thailand OLIC Company applying for Import Development products (FSN-013)
Fuji Pharma Co Ltd: Notice on the application for the selection of "gold market" in the division of new markets
Fuji Pharma Co Ltd: Notice on the decision on additional stock acquisitions in the stock remuneration system
No Data